393 related articles for article (PubMed ID: 35226558)
1. Evidence-Based Medical Therapy in Patients With Heart Failure With Reduced Ejection Fraction and Chronic Kidney Disease.
Beldhuis IE; Lam CSP; Testani JM; Voors AA; Van Spall HGC; Ter Maaten JM; Damman K
Circulation; 2022 Mar; 145(9):693-712. PubMed ID: 35226558
[TBL] [Abstract][Full Text] [Related]
2. Management of Heart Failure Patient with CKD.
Banerjee D; Rosano G; Herzog CA
Clin J Am Soc Nephrol; 2021 Jul; 16(7):1131-1139. PubMed ID: 33495289
[TBL] [Abstract][Full Text] [Related]
3. Personalizing heart failure management in chronic kidney disease patients.
Banerjee D; Wang AY
Nephrol Dial Transplant; 2022 Oct; 37(11):2055-2062. PubMed ID: 33591313
[TBL] [Abstract][Full Text] [Related]
4. Association of renin-angiotensin system inhibitors with long-term outcomes in patients with systolic heart failure and moderate-to-severe kidney function impairment.
Higuchi S; Kohsaka S; Shiraishi Y; Katsuki T; Nagatomo Y; Mizuno A; Sujino Y; Kohno T; Goda A; Yoshikawa T;
Eur J Intern Med; 2019 Apr; 62():58-66. PubMed ID: 30737061
[TBL] [Abstract][Full Text] [Related]
5. Association Between β-Blocker Use and Mortality/Morbidity in Patients With Heart Failure With Reduced, Midrange, and Preserved Ejection Fraction and Advanced Chronic Kidney Disease.
Fu EL; Uijl A; Dekker FW; Lund LH; Savarese G; Carrero JJ
Circ Heart Fail; 2020 Nov; 13(11):e007180. PubMed ID: 33070637
[TBL] [Abstract][Full Text] [Related]
6. Prevalence and clinical profile of kidney disease in patients with chronic heart failure. Insights from the Spanish cardiorenal registry.
Cobo Marcos M; de la Espriella R; Gayán Ordás J; Llàcer P; Pomares A; Fort A; Ponz de Antonio I; Méndez A; Blázquez-Bermejo Z; Caravaca Pérez P; Rubio Gracia J; Recio-Mayoral A; Zegrí I; García Pinilla JM; Montero Hernández E; Castro A; Soler MJ; Górriz JL; Bascompte Claret R; Fluvià-Brugués P; Manzano L; Núñez J
Rev Esp Cardiol (Engl Ed); 2024 Jan; 77(1):50-59. PubMed ID: 37217135
[TBL] [Abstract][Full Text] [Related]
7. Use of guideline-recommended medical therapy in patients with heart failure and chronic kidney disease: from physician's prescriptions to patient's dispensations, medication adherence and persistence.
Janse RJ; Fu EL; Dahlström U; Benson L; Lindholm B; van Diepen M; Dekker FW; Lund LH; Carrero JJ; Savarese G
Eur J Heart Fail; 2022 Nov; 24(11):2185-2195. PubMed ID: 35851740
[TBL] [Abstract][Full Text] [Related]
8. Safety of continuing mineralocorticoid receptor antagonist treatment in patients with heart failure with reduced ejection fraction and severe kidney disease: Data from Swedish Heart Failure Registry.
Guidetti F; Lund LH; Benson L; Hage C; Musella F; Stolfo D; Mol PGM; Flammer AJ; Ruschitzka F; Dahlstrom U; Rosano GMC; Braun OÖ; Savarese G
Eur J Heart Fail; 2023 Dec; 25(12):2164-2173. PubMed ID: 37795642
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of new medical therapies in patients with heart failure, reduced ejection fraction, and chronic kidney disease already receiving neurohormonal inhibitors: a network meta-analysis.
Ameri P; De Marzo V; Zoccai GB; Tricarico L; Correale M; Brunetti ND; Canepa M; De Ferrari GM; Castagno D; Porto I
Eur Heart J Cardiovasc Pharmacother; 2022 Dec; 8(8):768-776. PubMed ID: 34928347
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure).
Eschalier R; McMurray JJ; Swedberg K; van Veldhuisen DJ; Krum H; Pocock SJ; Shi H; Vincent J; Rossignol P; Zannad F; Pitt B;
J Am Coll Cardiol; 2013 Oct; 62(17):1585-93. PubMed ID: 23810881
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Mineralocorticoid Receptor Antagonists in Patients With Heart Failure and Chronic Kidney Disease.
Khan MS; Khan MS; Moustafa A; Anderson AS; Mehta R; Khan SS
Am J Cardiol; 2020 Feb; 125(4):643-650. PubMed ID: 31843235
[TBL] [Abstract][Full Text] [Related]
12. Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Data From the PARADIGM-HF Trial.
Srivastava PK; Claggett BL; Solomon SD; McMurray JJV; Packer M; Zile MR; Desai AS; Rouleau JL; Swedberg K; Fonarow GC
JAMA Cardiol; 2018 Dec; 3(12):1226-1231. PubMed ID: 30484837
[TBL] [Abstract][Full Text] [Related]
13. Trends in Kidney Function Outcomes Following RAAS Inhibition in Patients With Heart Failure With Reduced Ejection Fraction.
McCallum W; Tighiouart H; Ku E; Salem D; Sarnak MJ
Am J Kidney Dis; 2020 Jan; 75(1):21-29. PubMed ID: 31303349
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological interventions for heart failure in people with chronic kidney disease.
Lunney M; Ruospo M; Natale P; Quinn RR; Ronksley PE; Konstantinidis I; Palmer SC; Tonelli M; Strippoli GF; Ravani P
Cochrane Database Syst Rev; 2020 Feb; 2(2):CD012466. PubMed ID: 32103487
[TBL] [Abstract][Full Text] [Related]
15. Angiotensin Receptor-Neprilysin Inhibitors in Patients With Heart Failure With Reduced Ejection Fraction and Advanced Chronic Kidney Disease: A Retrospective Multi-Institutional Study.
Hsiao FC; Lin CP; Yu CC; Tung YC; Chu PH
Front Cardiovasc Med; 2022; 9():794707. PubMed ID: 35360037
[TBL] [Abstract][Full Text] [Related]
16. Contemporary Use of Sodium-Glucose Cotransporter-2 Inhibitor Therapy Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction in the US: The Get With The Guidelines-Heart Failure Registry.
Pierce JB; Vaduganathan M; Fonarow GC; Ikeaba U; Chiswell K; Butler J; DeVore AD; Heidenreich PA; Huang JC; Kittleson MM; Joynt Maddox KE; Linganathan KK; McDermott JJ; Owens AT; Peterson PN; Solomon SD; Vardeny O; Yancy CW; Greene SJ
JAMA Cardiol; 2023 Jul; 8(7):652-661. PubMed ID: 37212192
[TBL] [Abstract][Full Text] [Related]
17. Patient Management and Clinical Outcomes Associated with a Recorded Diagnosis of Stage 3 Chronic Kidney Disease: The REVEAL-CKD Study.
Tangri N; Peach EJ; Franzén S; Barone S; Kushner PR
Adv Ther; 2023 Jun; 40(6):2869-2885. PubMed ID: 37133647
[TBL] [Abstract][Full Text] [Related]
18. Heart Failure With Reduced Ejection Fraction: A Review.
Murphy SP; Ibrahim NE; Januzzi JL
JAMA; 2020 Aug; 324(5):488-504. PubMed ID: 32749493
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction: Results of DAPA-HF.
Jhund PS; Solomon SD; Docherty KF; Heerspink HJL; Anand IS; Böhm M; Chopra V; de Boer RA; Desai AS; Ge J; Kitakaze M; Merkley B; O'Meara E; Shou M; Tereshchenko S; Verma S; Vinh PN; Inzucchi SE; Køber L; Kosiborod MN; Martinez FA; Ponikowski P; Sabatine MS; Bengtsson O; Langkilde AM; Sjöstrand M; McMurray JJV
Circulation; 2021 Jan; 143(4):298-309. PubMed ID: 33040613
[TBL] [Abstract][Full Text] [Related]
20. Real-World Experience of Angiotensin Receptor-Neprilysin Inhibition in Reduced Ejection Fraction Heart Failure Patients With Advanced Kidney Disease.
Chang HY; Lin CC; Chao CJ; Lin YC; Wang YC; Liao CT; Huang JL; Lee YH; Huang CY; Chien LN; Hsu CY
Mayo Clin Proc; 2023 Jan; 98(1):88-99. PubMed ID: 36109207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
